Drug Trial Radar · NCT04806893
Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction
Last checked: Nov 20, 2026Latest source record: Dec 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
900
Planned (sponsor's estimate)
Start
Apr 22, 2021
Primary completion
Nov 15, 2023
Study completion Feb 28, 2024
Sponsor
- Lead sponsor
- LIB Therapeutics LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- Mar 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to assess LDL-C reductions at Week 52 with monthly (Q4W \[≤31 days\]) dosing of LIB003 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with CVD, or at high risk for CVD, on a stable diet and oral LDL-C lowering drug therapy
Conditions
- Cardiovascular Risk Factor
- Cardiovascular Diseases
- Cardiovascular Stroke
- Hypercholesterolemia
Interventions
lerodalcibepDrug
300 mg subcutaneous injection every month (Q4W)
PlaceboOther
matching subcutaneous injection every month (Q4W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- LDL-C change compared to placeboTime frame: 52 weeks
- mean LDL-C change at week 50 and 52Time frame: 50 and 52 weeks
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
Sterling Research Group
Cincinnati, Ohio
The Lindner Research Center
Cincinnati, Ohio
Metabolic & Atherosclerosis Research Center (MARC)
Cincinnati, Ohio
G.B. Pant Institute of Postgraduate Medical Education & Research
New Delhi, India
Department of Medicine, Hadassah University Hospital
Jerusalem, Israel
Rabin Medical Center, Beilinson Hospital,
Petah Tikva, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.